Blenrep for Multiple Myeloma Withdrawn From US Market

The manufacturer is pulling the drug from the market at the request of the FDA following disappointing results from a large phase 3 confirmatory trial.

Related Keywords

Sabine Luik ,Drug Administration ,Medical Officer Sabine ,Multiple Myeloma ,Myeloma ,Plasma Cell Myeloma ,Chimeric Antigen Receptort Cell Therapy ,Chimeric Antigen Receptors ,Himeric Immunoreceptors ,Himerict Cell Receptors ,Rtificialt Cell Receptors ,Ar T ,Antigens ,Biologic Therapy ,Antibody Drug Conjugates Adcs ,Clinical Research ,Clinical Trials ,Linical Studies ,Grant ,Proteasome Inhibitor ,Bortezomib ,Receptors ,Refractory ,Healthcare And Medical T ,